Insmed :
INSM
INSM
Stock Data
$159.74
$0.47 (0.30%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Insmed Inc is a biopharmaceutical firm focused on developing and marketing treatments for patients with serious and rare diseases globally. Its flagship product, ARIKAYCE, targets Mycobacterium avium complex lung disease in adults. The company is also working on Brensocatib for bronchiectasis and other diseases, and Treprostinil Palmitil Inhalation Powder for certain types of pulmonary hypertension. Founded in 1988, Insmed is based in Bridgewater, New Jersey, serving patients in the US, Europe, Japan, and beyond.
All Insmed Articles
7 Articles